Charles River Laboratories International Signs $470M M&A Deal with Frontage Holdings Corporation
Charles River Laboratories has entered into definitive agreements to acquire Frontage Holdings Corporation’s bioanalysis and DMPK operations in Exton, Pennsylvania for $470 million in cash. The deal includes up to $75 million in additional contingent payments and is intended to expand Charles River's clinical bioanalysis capabilities to support clients across the full drug development lifecycle. The transaction is expected to close in the first half of 2027.
- Value
- $470M
- Counterparty
- Frontage Holdings Corporation